00:00Moderna and Merck are celebrating a major milestone after their personalized mRNA cancer treatment
00:06succeeded in a late-stage trial involving more than 1,100 melanoma patients. The treatment given
00:12alongside Merck's Keytruda reduced the risk of melanoma returning or spreading compared with
00:18Keytruda alone, marking the first successful late-stage trial for an mRNA-based cancer
00:23treatment. Moderna shares surged as much as roughly 160 percent after the announcement,
00:30while Merck also jumped sharply. The companies now face the next test,
00:34regulatory review, and broader confirmation of the results.
